Siderophore Cephalosporin Antibiotic with a 'Trojan Horse' Mechanism

A new super antibiotic that can provide a new treatment opportunity for patients with multidrug-resistant Gram-negative bacterial infections, which are untreatable with existing antibiotics, has been launched in Korea.


Jeil Pharmaceutical Launches Super Antibiotic 'Fetroja'... Hope for Treating Severe Infections View original image

On February 2, Jeil Pharmaceutical announced the launch of Fetroja (ingredient name: cefiderocol), a siderophore cephalosporin antibiotic.


Fetroja is a new drug developed by Shionogi Pharmaceutical of Japan. Jeil Pharmaceutical signed an exclusive domestic supply agreement with Shionogi in 2022, and after obtaining approval from the Ministry of Food and Drug Safety and insurance coverage, the product is set to launch this month. This is the first time a siderophore cephalosporin antibiotic with a 'Trojan horse' mechanism has been launched in Korea.


Fetroja is a super antibiotic that can offer a new treatment option for patients with multidrug-resistant Gram-negative bacterial infections who cannot be treated with existing antibiotics. It is expected to provide a practical alternative in the medical field, where there has been a lack of appropriate treatment options despite the rapid increase in domestic cases of antimicrobial resistance (AMR).


This antibiotic is the first in the world to implement the so-called Trojan horse mechanism, utilizing the iron absorbed by bacteria for survival to penetrate inside the bacteria. This has the effect of neutralizing the defensive barriers of highly resistant bacteria that previously blocked the entry of existing antibiotics.


In particular, it is expected to play a crucial role as a last-resort treatment for patients with severe infections for whom existing therapies are extremely limited, such as those with complicated urinary tract infections (cUTI) and hospital-acquired pneumonia (HABP/VABP), including carbapenem-resistant Enterobacteriaceae (CRE).



A Jeil Pharmaceutical representative stated, "Antimicrobial resistance is one of the major challenges facing modern medicine, and Fetroja is significant in that it offers a new treatment option for patients who have suffered due to the lack of appropriate therapies. We will continue to provide innovative solutions so that healthcare professionals can more effectively treat multidrug-resistant Gram-negative bacterial infections."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing